Drugs / VDMN-21
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05799157 | Feb 2023 → Feb 2025 | common wart | Veradermics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VDMN-21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05799157 ↗ |
| Route | Topical | “Low does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed.” NCT05799157 ↗ |